Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS)
Roncolato, F.T., O'Connell, R.L., Joly, F., Lanceley, A., Hilpert, F., Buizen, L., Okamoto, A., Aotani, E., Salutari, V., Donnellan, P., Oza, A., Avall-Lundqvist, E., Berek, J., Fehm, T., Ledermann, JJournal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2019.10.001
Date:
December, 2019
File:
PDF, 753 KB
2019
File converter
More search results
More benefits 
